Annunciati risultati promettenti per intismeran autogene, una terapia sperimentale

Pharmaceutical companies Merck, known as MSD outside the United States and Canada, and Moderna announced on Wednesday that their individualized neoantigen therapy, intismeran…

A phase 3 trial found that a combination of intismeran autogene plus pembrolizumab improved recurrence-free and distant metastasis-free survival in patients with high-risk…